Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation (SANA)
· seekingalpha.com
Sana Biotechnology's lead asset still remains to be SC291, repurposed for severe autoimmune disorders instead of blood cancers. See why SANA stock is a buy.
Sana Biotechnology, Inc. ( SANA ) has recently undergone a big pipeline reset . Up to 2024, they mainly focused on oncology, specifically blood cancers, but aft...